While malignant brain tumors typically show high choline concentrations and neovascularity, we have anecdotally noted that a substantial number of brain metastases from lung cancer demonstrate only mildly elevated choline resonances on proton MR spectroscopy ( 1 H-MRS).
Introduction
Brain metastases are the most common intracranial tumors in adults, occurring at least 10 times more frequently than primary brain tumors (1) and in anywhere from 20% to 40% of cancer patients (2) . Diagnosis of brain metastases is usually made on the basis of clinical and imaging findings, but when clinical history is unavailable or noncontributory, detection of an enhancing brain lesion on conventional cross Technology in Cancer Research & Treatment, Volume 9, Number 4, August 2010 sectional imaging invokes a much broader list of both malignant and benign differential considerations. In fact, even in patients with known extracranial malignancies, as many as 11% of solitary brain lesions identified on MRI may represent processes other than metastases (3) .
In these cases, adjunctive tests such as proton MR spectroscopy ( 1 H-MRS) and MR perfusion weighted imaging (PWI) can be helpful both in distinguishing malignant from benign lesions and in differentiating primary brain tumors from metastases (4) (5) (6) (7) (8) . Malignant brain tumors tend to demonstrate both high choline concentrations and increased vascularity. We have previously noted that lung cancer metastases demonstrate, on average, lower Cho/Cr compared to metastases from other types of cancer (9), and it has also been our empiric observation that a substantial number of lung cancer metastases show Cho/Cr ratios which may even overlap those of normal tissues (between 0.5 and 1.5).
Why these metastases fail to demonstrate appreciable elevations in Cho/Cr is not entirely clear, but growing evidence points toward variations in expression of choline kinase (ChoK), an enzyme involved in cellular choline metabolism, as a potential culprit. ChoK is overexpressed in a number of malignancies, and levels of the enzyme have been shown to correlate with tumoral levels of total choline (10-16). Interestingly, ChoK expression is regulated in part by the actions hypoxia inducible factor-1 (HIF-1) (16), a transcription factor which also regulates expression of a large number of cellular factors involved in tumor angiogenesis, including vascular endothelial growth factor (VEGF) (17, 18) .
It stands to reason, therefore, that if both choline concentration and angiogenesis in malignant tumors are potentially mediated through the actions of HIF-1 (through its upregulation of ChoK and VEGF expression, respectively), one should see a correlation between choline concentrations seen on 1 H-MRS and measures of tissue vascularity, such as relative cerebral blood volume (rCBV) derived from PWI.
The purposes of this study were two fold: 1) to assess whether untreated lung cancer metastases to the brain are more likely to demonstrate low choline (i.e. Cho/Cr < 2.0) than metastases from other malignancies; and 2) to assess whether there is an association between Cho/Cr and relative cerebral blood volume (rCBV) measurements in brain metastases.
Materials and Methods

Study Population
We performed a retrospective analysis of cancer patients at our institution with newly diagnosed, untreated brain metastases who underwent conventional brain MRI and multivoxel brain 1 H-MRS between January, 1999 and June, 2007 . For this study, we focused specifically on the three most common cancers to metastasize to the brain: lung cancer, breast cancer, and melanoma, which collectively represent 67% to 71% of brain metastases (1, 19) . Patients were excluded from the analysis if: 1) the metastases had been previously treated with stereotactic or whole brain radiation; and/or 2) the largest brain metastasis was less than 1 cm in size. The diagnosis of metastatic brain disease was made either on the basis of histology from brain biopsy or clinically on the basis of finding a new enhancing brain lesion in a patient with a known histologically confirmed primary extracranial tumor.
A total of 67 patients met initial inclusion criteria: 41 with lung cancer, 17 with breast cancer, 9 with melanoma. As only one lung cancer patient had a diagnosis of small cell lung cancer (SCLC), we elected to exclude this patient and to focus exclusively on those with non-small cell lung cancer (NSCLC), leaving a total of 40 lung cancer patients and 66 patients overall for analysis. Twenty-three patients (14 lung, 6 breast, and 3 melanoma) underwent biopsy of their intracranial lesions to confirm the diagnosis of metastasis.
Conventional MR Imaging
All MR imaging was performed on 1.5 Tesla MR units (Vision, Sonata, or Avanto, Siemens Medical Systems, Erlangen, Germany) using a single-channel head coil. Our conventional imaging protocol consists of a three-plane localizer sequence; axial and sagittal T1-weighted images; axial FLAIR and fast spin-echo T2 weighted sequences; and gadolinium-enhanced axial, sagittal, and coronal T1-weighted images through the entire brain. The conventional MRI images were reviewed by a board-certified neuroradiologist who assessed the number and size (greatest diameter) of brain metastases on the axial contrast-enhanced images.
MR Spectroscopy
We performed 1H-MRS utilizing a 2-dimensional point resolved multi-voxel spectroscopic imaging technique (2D PRESS chemical shift imaging; 2D CSI) provided by the MR vendor. Spectroscopic imaging was performed after administration of gadopentetate-dimeglumine and was planned off the gadolinium-enhanced images. After re-shimming (H 2 O w 1/2 12 Hz), data were obtained at a TE = 135 msec and TR = 1460 msec with 4-9 averages. We utilized a 16 × 16 scan matrix with a FOV of 160 mm and a slice thickness of 0.5 cm to 1.5 cm. The acquisition time for the 2D CSI study varied between 7-12 minutes depending on the volume size used in the CSI study (0.5-1.5 cc/voxel). Between 4-6 saturation bands were used for outer volume suppression. The spectroscopic data obtained from the study were processed on an offline workstation with software provided by the MR vendor.
rCBV. Mean maximal rCBV values were calculated for the contralateral normal appearing white matter in the patient and used as an internal standard. Normalized rCBV ratios (rCB-V norm ) were computed as the ratio between the rCBV within the tumor and the rCBV in the contralateral normal appearing white matter. In patients with more than one lesion, measurements were taken from the lesion analyzed on 1 H-MRS.
Statistical Analysis
Because Cho/Cr was not normally distributed in our sample, non-parametric tests were used for comparisons of Cho/Cr. Mean and median maximum tumoral Cho/Cr were calculated for each tumor group. Mann-Whitney U tests were used to identify significant Cho/Cr differences between the different histologic groups. Within each group we also assessed for potential correlations between lesion size and Cho/Cr using a two-tailed Spearman rank correlation test.
Various authors have suggested Cho/Cr threshold values ranging from 1.55 to 2.48 for distinguishing benign from malignant tissue in the brain (23-25); on the basis of our own clinical 1 H-MRS experience, we empirically use a Cho/ Cr threshold of 2.0 or greater to indicate malignancy, with Cho/Cr ratios between 1.5 and 2.0 being suspicious but not specific for active metabolic processes such as inflammation and tumor, and Cho/Cr ratios < 1.5 being normal. We therefore dichotomized lesions into two groups based on Cho/Cr: those with maximal Cho/Cr less than 2.0 (designated as low Cho/Cr) and those with Cho/Cr greater than or equal to 2.0 (designated high Cho/Cr). 2 × 2 contingency tables were created to compare relative Cho/Cr level between the different primary tumor types (i.e., lung vs. breast, lung vs. melanoma, and breast vs. melanoma), and two-tailed Fisher exact tests were performed to determine if significant differences in the distribution of Cho/Cr existed between histologic groups.
To assess for an association between Cho/Cr from 1 H-MRS with rCBV norm from PWI in the 20 patients who underwent both tests, we used a two-tailed Spearman rank correlation test. In addition, we used a Mann-Whitney U test to determine whether there was a significant difference in rCBV norm between metastases showing low Cho/Cr and those showing high Cho/Cr. For all statistical analyses, a p-value < 0.05 was chosen to indicate statistical significance. All statistical analyses were performed using SPSS version 16.0 (SPSS, Chicago, Illinois).
Results
Mean patient age was 56.0 ± 1.4 years (± standard error). Males comprised 34.8% of the sample. The mean number
The time domain signal was filtered using a Gaussian filter (5 Hz), zero-filled to 1024 data points, and a Fourier transform was performed to obtain the frequency spectral domain information. A polynomial baseline correction was applied and the phase of the resonance signals corrected. After spectral processing, metabolite peaks were assigned as follows: choline, 3.2 ppm; creatine, 3.0 ppm; N-acetylaspartate, 2.0 ppm. These spectral regions were then curve fitted with a program supplied by the vendor for determination of the peak area under the fitted resonance peak. Spectroscopic data from each voxel were expressed as intratumoral metabolite peak area ratios (e.g., Cho/Cr). In this multivolume analysis of each tumor, the volume only within the enhancing portions of the lesion (presumed to represent viable tumor) giving highest Cho/Cr ratio was selected. In patients with multiple lesions, measurement was taken from the largest lesion identified on conventional imaging.
Because histologic sampling from the brain was not performed in a majority of cases, we also evaluated the spectra from peritumoral tissue to support the diagnosis of metastasis over a primary brain tumor. Law et al., demonstrated that Cho/Cr is significantly elevated in peritumoral tissue adjacent to the enhancing portions of high grade gliomas, but not in peritumoral tissue adjacent to metastases (4) . None of the patients in our sample demonstrated elevated Cho/Cr in the tissue outside of the areas of enhancement, supporting the diagnosis of metastatic disease.
Perfusion weighted MR Imaging and Measurement of rCBV
Twenty-one patients (15 NSCLC, 4 breast cancer, 2 melanoma) also underwent dynamic susceptibility contrastenhanced MR perfusion weighted imaging (PWI) of the brain. Single-shot GRE echo-planar images (TR/TE 2000/54; flip angle 60º; matrix size 128 × 128; FOV 230 mm) were acquired before, during, and after the first pass of a rapid contrast bolus (gadopentetate dimeglumine, 0.1 mmol/kg) administered through an 18-gauge IV line. Each study consisted of sequential acquisitions of 40 single-shot echo-planar images of 20 sections each for a total of 800 images. The perfusion data were processed with Perfusion Task Card software provided to us by the Massachusetts General Hospital, A. A. Martinos Center for Biomedical Imaging (20-22) on a freestanding workstation to determine rCBV. Ratios of tumor to contralateral normal brain rCBV (rCBV ratio) were calculated in a fashion previously described by Law et al., (4) . Within the tumors, 1-4 regions of interest (ROI) with the highest rCBV value were selected and recorded. If more than one ROI was selected, the ROIs were averaged, and the average value was used to represent the rCBV for the tumor. When multiple ROIs were obtained, each ROI measured approximately 3-5 mm in diameter. Selection of smaller ROIs allowed acquisition of measurements from tumor volumes with the highest Technology in Cancer Research & Treatment, Volume 9, Number 4, August 2010 Differences observed between NSCLC and melanoma metastases (p = 0.14) and between breast cancer and melanoma metastases (p = 0.75) were not statistically significant.
For the entire sample, there was a weak but significant correlation between metastasis size and Cho/Cr (ρ = 0.436, p < 0.001). Lesion size and Cho/Cr were weakly correlated among NSCLC metastases (ρ = 0.343, p = 0.03) and moderately correlated among breast cancer metastases (ρ = 0.617, p = 0.008). A significant correlation between size and Cho/ Cr was not observed among metastases from melanoma (ρ = 0.602, p = 0.11). of lesions per patient was 2.3 ± 0.3, and 56.1% of patients had a solitary metastasis. Mean lesion size was 2.5 ± 0.2 cm. Color maps of Cho/Cr, spectral maps, and selected spectra of representative brain metastases from patients with NSCLC, breast cancer, and melanoma are shown in Figures 1-4 .
Mean and median Cho/Cr values for each tumor type are shown in Table I . Mean and median Cho/Cr were lowest in the NSCLC group (3.0 and 2.6, respectively). There was a significant difference between Cho/Cr from NSCLC metastases and breast cancer metastases (p = 0.047). Figure 1 : CSI 1 H-MRS (TE = 135 msec) Cho/Cr color map (A) and spectral map (b) from a brain metastasis due to NSCLC demonstrating elevated Cho/Cr (≥2.0). The spectrum from the enhancing intratumoral voxel on the spectral map giving the highest Cho/Cr is shown in (c). Metabolite peaks were assigned as follows: Cho, 3.2 ppm; Cr, 3.0 ppm; NAA, 2.0 ppm. Note in (c) that the choline peak is substantially larger than the nearby creatine peak. A lipid peak centered at approximately 1.3 ppm is also noted, which may reflect necrosis or loosening of lipid myelin sheath components or cellular membrane processes leading to lipid methylene groups becoming visible. (Cho = Choline; Cr = Creatine; NAA = N-acetylaspartate). cancer metastases (p = 0.37) or between breast cancer and melanoma metastases (p = 0.26).
Among the 21 patients who also underwent PWI of their lesions, mean and median Cho/Cr of the lesions were 3.1 and 2.8, respectively. Respective mean and median Cho/Cr were 2.5 and 2.7 (range 0.7 to 5.7) for the 15 NSCLC metastases; 3.2 and 3.1 (range 1.6 to 4.9) for the 4 breast cancer metastases; and 7.9 and 7.9 (range 6.2 to 9.5) for the two melanoma metastases. Mean and median rCBV norm were 2.41 and 2.10 respectively. Respective mean and median rCBV norm were 1.99 and 1.82 (range 1.12 to 3.92) for the NSCLC For the total patient sample, 28.8% (19/66) had metastases demonstrating low Cho/Cr (< 2.0). Low Cho/Cr was observed in 37.5% (15/40) of lung cancer metastases, in 23.5% (4/17) of breast cancer metastases, and in 0/9 of the melanoma metastases (Table II) .
2 × 2 contingency tables comparing pairs of tumor types demonstrated a statistically significant difference between NSCLC and melanoma metastases (p = 0.04), indicating that lung cancer metastases were significantly more likely to demonstrate low Cho/Cr than melanoma metastases. Significant differences were not observed between lung and breast Figure 2 : CSI 1 H-MRS (TE = 135 msec) Cho/Cr color map (A) and spectral map (b) from a brain metastasis due to NSCLC demonstrating low Cho/Cr (<2.0). The spectrum from the enhancing intratumoral voxel on the spectral map giving the highest Cho/Cr is shown in (c). Metabolite peaks were assigned as follows: Cho, 3.2 ppm; Cr, 3.0 ppm; NAA, 2.0 ppm. Note in (c) that the choline peak is smaller than the adjacent creatine peak. A lipid peak centered at approximately 1.3 ppm is also present. (Cho = Choline; Cr = Creatine; NAA = N-acetylaspartate). 
Discussion
Elevated concentrations of choline seen in tumors on 1 H-MRS presumably reflect increased membrane synthesis or tumor cellularity relative to normal tissue. There is no widely accepted Cho/Cr cutoff for distinguishing benign from malignant processes in the brain. Although our Cho/ Cr cutoff of 2.0 is somewhat arbitrary and based on our own empiric observations, this value falls well within the range of other authors' suggested threshold values (23-25). However, we found that using a Cho/Cr cutoff of 2.0 resulted in a false negative result in over a quarter of brain metastases. metastases; 2.78 and 2.95 (range 1.5 to 3.7) for the breast cancer metastases; and 4.80 and 4.80 (range 3.20 to 6.40) for the melanoma metastases. Cho/Cr and rCBV norm showed a strong and significant correlation (Spearman's p = 0.847, p < 0.001). A scatter plot of Cho/Cr versus rCBV norm is shown in Figure 5 .
Seven patients undergoing PWI fell in the low Cho/Cr group, and 14 fell in the high Cho/Cr group. Mean and median rCBV norm for the two Cho/Cr groups are shown in Table III . rCBV norm was significantly higher in the high Cho/Cr group compared to the low Cho/Cr group (p = 0.001). and spectral map (b) from a brain metastasis due to breast cancer demonstrating elevated Cho/Cr. The spectrum from the enhancing intratumoral voxel on the spectral map giving the highest Cho/Cr is shown in (c). Metabolite peaks were assigned as follows: Cho, 3.2 ppm; Cr, 3.0 ppm; NAA, 2.0 ppm. The choline peak in (c) is substantially larger than the nearby creatine peak. A lipid peak centered at approximately 1.3 ppm is also noted. (Cho = Choline; Cr = Creatine; NAA = N-acetylaspartate).
Although mean and median Cho/Cr were both lowest among the NSCLC group, the observed Cho/Cr difference between NSCLC metastases and melanoma metastases did not achieve statistical significance despite the fact that significantly more Specifically, 37.5% of NSCLC metastases and 23.5% of breast cancer metastases would be misdiagnosed by our strict Cho/Cr criteria. Of note, lowering the Cho/Cr cutoff to 1.50 would only have improved our overall false negative rate to 14.7%, with 22.5% of NSCLC metastases and 5.9% of breast cancer metastases still being categorized as noncancerous. Therefore one should exercise caution in using 1 H-MRS data alone to exclude the possibility of malignancy in a patient with an enhancing brain lesion, particularly when there is a concomitant history of NSCLC or breast cancer. Furthermore, when 1 H-MRS is used to monitor treatment response of lung cancer metastases, absolute Cho/ Cr ratios alone may not be helpful in distinguishing viable tumor from benign tissue in cases where baseline Cho/Cr levels were already low. Figure 4 : CSI 1 H-MRS (TE = 135 msec) Cho/Cr color map (A) and spectral map (b) from a brain metastasis due to melanoma demonstrating elevated Cho/Cr. The spectrum from the enhancing intratumoral voxel on the spectral map giving the highest Cho/Cr is shown in (c). Metabolite peaks were assigned as follows: Cho, 3.2 ppm; Cr, 3.0 ppm; NAA, 2.0 ppm. The choline peak in (c) is substantially larger than the nearby creatine peak. A lipid peak centered at approximately 1.3 ppm is also present. (Cho = Choline; Cr = Creatine; NAA = N-acetylaspartate). levels are upregulated by the actions HIF-1 (16, 17) , which is known to be highly expressed in a number of cancers and their metastases (28). Normally, HIF-1 is stabilized in hypoxic conditions and is rapidly degraded at normal oxygen tensions, but it has been shown that HIF-1 is also overexpressed in a number of cancer cell types under normoxic conditions (29). Based on our findings, we posit that Cho/Cr and rCBV may both represent surrogate measures of HIF-1 activity within brain metastases, due to its dual effects upon ChoK and VEGF expression. Further evidence of the influence of HIF-1 on tumor choline concentrations can be found in a study by Griffiths et al., (30) , who demonstrated that mouse hepatoma tumors deficient in the β-subunit of HIF-1 (HIF-1β) contained significantly lower levels of total choline, free choline, and phosphocholine compared to wild type tumors. Similarly, it has been shown that expression of the a-subunit of HIF-1 (HIF-1a) correlates with tumor grade and degree of neovascularization in gliomas (31), likely through its effects on VEGF.
We postulate that metastases in our study with low Cho/Cr may represent a population of tumors which express relatively low levels of HIF-1. It is clear that the range of HIF-1 expression in extracranial malignancies is highly variable, even within specific cancer types. Immunohistochemical studies have demonstrated that roughly half of primary malignant tumors fail to overexpress HIF-1 (28, 32-34). Therefore it would not be unexpected to see similar variability of HIF-1 in brain metastases. Why low Cho/Cr was seen only in NSCLC and breast metastases, but not in melanoma metastases remains unclear, however. HIF-1 has been shown to be a key regulator of metastasis in various cancers (35, 36) , and Zhong et al., showed that while only 29% of primary breast cancers overexpressed HIF-1a, 69% of breast metastases were NSCLC metastases than melanoma metastases did fall into the low Cho/Cr category (37.5% vs. 0% respectively). In addition, although the median Cho/Cr was significantly higher among NSCLC patients than among breast cancer patients, and substantially more patients with NSCLC than breast cancer had metastases with Cho/Cr < 2 (37.5% vs. 23.5%, respectively), the latter proportional difference was not statistically significant. We suspect that our inability to reject the null hypotheses in these instances may have been a consequence of insufficient statistical power due to the relatively small numbers of patients analyzed coupled with the fairly broad distributions of Cho/Cr observed, particularly among the NSCLC and melanoma metastases.
Perhaps not surprisingly, we found a strong positive association between Cho/Cr and rCBV in brain metastases, which begs the question of how tumor choline levels are related to tumor perfusion. Numerous studies suggest that expression of ChoK plays an important role in carcinogenesis and may be primarily responsible for the increased tumoral choline resonances seen on in vivo 1 H-MRS (10, 11, (13) (14) (15) (16) . Following transport of extracellular choline across the plasma membrane, ChoK phosphorylates choline into phosphocholine, which studies suggest is the major contributor to the increased total choline signal observed in tumors on in vivo 1 H-MRS (16, 26) . Furthermore, it is recognized that rCBV in brain tumors -a surrogate measure of angiogenesis and tumor grade (18, 27) -correlates with expression of vascular endothelial growth factor (VEGF), which has also been shown to be highly expressed in malignant tumors (18). As was mentioned earlier, both ChoK activity and VEGF Cho/Cr = choline-to-creatine ratio. 1 Distributions differed significantly (p = 0.042). Cho/Cr = choline-to-creatine ratio; rCBV norm = normalized rCBV ratio; SE = standard error. 1 Differed significantly (p = 0.001).
Figure 5:
Scatter plot of tumor Cho/Cr versus rCBV norm in 21 patients with brain metastases. There was a strong positive correlation between Cho/Cr and normalized rCBV (ρ = 0.847; p < 0.001). A best fit linear regression line is also shown (r 2 = 0.783; p < 0.001). positive (28), suggesting that in some instances, the ability to metastasize may be partially dependent upon HIF-1 expression. It is possible that NSCLC and breast cancer are more likely to metastasize to the brain at lower levels of HIF-1 expression compared to melanoma.
We acknowledge that the above discussion is largely speculative. Further investigation directly linking these MRI metrics from 1 H-MRS and rCBV with tissue immunohistochemical assays for the presence of HIF-1 are required to confirm our hypotheses. Nonetheless, our findings suggest avenues for future investigation into the potential role of HIF-1 on choline metabolism and tumor perfusion in metastatic carcinomas of the lung and breast. For example, studies have demonstrated that tumors deficient in HIF-1 grow more slowly and are more radiosensitive than wild type tumors (37), and lung and breast cancers expressing low levels of HIF-1 carry a better prognosis than those which overexpress 38, 39) . By extension we might expect metastases deficient in HIF-1 to also be more responsive to radiotherapy and/or carry a better prognosis. If this were the case and it could be established that choline levels measured on 1 H-MRS or rCBV measured from PWI are, in fact, reliable surrogate markers for HIF-1 overexpression, these noninvasive indicators could ultimately be used as prognostic indicators in patients with brain metastases.
Several limitations of our study should be noted. We lacked confirmatory histologic proof on nearly two-thirds of the brain lesions in our sample. It is not the standard practice at our institution to biopsy every brain metastasis prior to initiating therapy, as this would be impractical and unnecessary, particularly when diagnosis can be confidently established on clinical and imaging grounds. In general, biopsy is reserved for cases in which there remains uncertainty as to diagnosis after all options for noninvasive characterization have been exhausted. Therefore, it is possible, though unlikely, that some of the lesions included in our sample were not metastases.
We did not specifically attempt to measure rCBV in the same location as the voxel from which we measured Cho/Cr but rather averaged rCBV values over ROIs through the enhancing portions of the metastases. Therefore, it is likely that the rCBV norm values used in our correlation analysis were at least slightly different than values we would have obtained were we able to draw ROIs corresponding exactly to the voxels used in our spectroscopic analysis. Because the spectral maps were not coregistered to the rCBV maps and because of the relatively low resolution of the PWI images however, we could not have ensured that a given ROI placed manually on a lesion would correspond exactly to the voxel used in the 1 H-MRS analysis. We therefore elected to use multiple ROIs which we then averaged to represent the rCBV for the entire lesion, using the method previously described by Law et al., (4) .
The fact that lung cancer patients undergoing 1 H-MRS almost exclusively had NSCLC suggest that there was some element of bias in the selection of patients for 1 H-MRS, which may be related to different imaging protocols at our institution for patients with SCLC and NSCLC. As such, it would not be appropriate to generalize our findings to patients with SCLC. In addition, our decision to exclude cancers other than lung, breast, and melanoma precludes us from drawing conclusions about metastases from other sites.
Our choice to only include the single largest metastasis for analysis from patients with multiple lesions was based on the assumption that the largest lesion was most likely to have the highest level of choline metabolism, but because spectroscopy was not performed on every lesion in patients with multiple metastases, we cannot be certain that this was actually the case. Exclusion of these smaller lesions could have resulted in our results being biased in favor of a positive result. However, in those patients in whom 1 H-MRS was performed on multiple lesions, we did not find substantially higher Cho/Cr values in smaller lesions which would have led to recategorization of patients from the low Cho/Cr group into the high Cho/Cr group.
Conclusion
We have shown that substantial number of brain metastases due to NSCLC and breast cancer demonstrate low choline on 1 H-MRS. Thus demonstration of low Cho/Cr by a lesion should not deter one from suggesting the diagnosis of metastatic disease when conventional MRI shows an enhancing brain lesion in a patient with a known lung or breast cancer. We also showed that Cho/Cr and rCBV in brain metastases are highly correlated. Although the reasons behind these observations remain unclear, we believe that expression of the transcription factor HIF-1 likely plays a central role in these findings. If this were the case, then our data suggest that these noninvasive MRI metrics could be used as noninvasive measures of the activity of HIF-1 within metastatic lesions and could potentially serve as predictors of tumor behavior, including responsiveness to radiotherapy and disease prognosis.
